Relationship between plasma Neuregulin-1 and cardiac function in patients with ST-elevation myocardial infarction

Rev Cardiovasc Med. 2022 Feb 14;23(2):63. doi: 10.31083/j.rcm2302063.

Abstract

Background: Neuregulin-1 (NRG-1) is a stress-mediated transmembrane growth factor. Reduced myocardial damage and higher NRG-1 levels upon treatment with remote ischemic conditioning (RIC) has been described in rats. However, the role of NRG-1 in patients with acute myocardial infarction (MI) is unknown. Thus, we conducted a post hoc analysis of a randomized controlled trial that tested RIC in patients with MI scheduled for primary percutaneous coronary intervention (PCI).

Methods: Blood was drawn from 30 patients before RIC/PCI, within 1 hour, 4 days and 1 month later. Median left ventricular ejection fraction (LVEF) in the overall study population following MI was 48.5%.

Results: NRG-1 plasma levels decreased significantly following PCI/RIC and remained decreased up to 1 month following MI (p < 0.0001). We observed no association of NRG-1 with other variables, including total ischemic time, LVEF or RIC.

Conclusions: Thus, we identified NRG-1 may be independently affected by MI. However, further large clinical trials are warranted to clarify this hypothesis.

Keywords: Neuregulin-1; acute myocardial infarction; biomarker; left ventricular function.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Humans
  • Neuregulin-1
  • Percutaneous Coronary Intervention* / adverse effects
  • Rats
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / therapy
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Function, Left

Substances

  • Neuregulin-1